


Imugene thrilled as first patients dosed in VAXINIA MAST combination study



NEWS RELEASE BY IMUGENE LTD

Melbourne, Victoria | March 03, 2023 11:40 AM Eastern Standard Time

Imugene Limited (ASX: IMU) CEO Leslie Chong tells Proactive the company's Phase 1 MAST (metastatic advanced solid tumours) study evaluating the safety of novel cancer-killing virus CF33-hNIS (VAXINIA) has seen the first patients dosed in the intravenous and intratumoral (IT) cohorts in combination with Pembrolizumab. Overall the study aims to recruit up to 100 patients across around 10 trial sites in the United States and Australia.



Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Jonathan@proactiveinvestors.com

Tags

IMUGENE LIMITED

CANCER

BIOTECH

ASX

PROACTIVEAUSTRALIA

PROACTIVEINVESTORS